Goldman Sachs’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

Goldman Sachs’s Portfolio EUCR Stock Details EUCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-30,622	Closed	-$307K	–	6406
2022 Q3	$307K	Sell	30,622 -25,000	-45%	-$249K	﹤0.01%	5292
2022 Q2	$550K	Sell	55,622 -498,000	-90%	-$4.92M	﹤0.01%	5013
2022 Q1	$5.45M	Buy	553,622 +518,510	+1,477%	+$5.09M	﹤0.01%	3275
2021 Q4	$343K	Sell	35,112 -2,090	-6%	-$20.5K	﹤0.01%	5599
2021 Q3	$364K	Buy	37,202 +26,103	+235%	+$255K	﹤0.01%	5387
2021 Q2	$109K	Buy	+11,099	New	+$109K	﹤0.01%	5926

Other funds holding EUCR

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

SIA

SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Goldman Sachs's EUCR Position: Q4 2022 in Review

Goldman Sachs sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q4 2022, closing a stake of 30,622 shares — an estimated $307K sold.

Goldman Sachs first reported a position in EUCR in Q2 2021 and held it in 6 quarters. The position peaked at $5.45M in Q1 2022. 5 funds tracked by Wall St. Rank hold EUCR as of Q4 2022.

Goldman Sachs reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Goldman Sachs sold 30,622 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q4 2022, an estimated $307K.
Goldman Sachs first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q2 2021 and held it in 6 quarters.
Goldman Sachs's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $5.45M in Q1 2022.
5 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q4 2022.

Based on Goldman Sachs's 13F filing for Q4 2022, filed 13 Feb 2023.